ft 24 mar 94 uk compani news glaxo grant wellcom option 3tc drug glaxo grant wellcom option develop market compound 3tc final clinic trial treatment hiv viru glaxo licens drug biochem pharma canada 1990 would continu clinic develop compound treatment hepat b part current trial hiv involv use 3tc conjunct wellcom anti aid drug retrovir glaxo said increas evid combin therapi promis approach hiv treatment propos arrang would repres effici way bring 3tc market wellcom like decid whether exercis option trial result avail toward end year would trigger payment glaxo market wellcom would make royalti payment glaxo base sale glaxo turn would pay royalti biochem pharma glaxo 17 per cent stake biochem research base pharmaceut compani form 1986 quot montreal toronto stock exchang nasdaq